Skip to main content
. 2023 Jan 25;15(3):614. doi: 10.3390/nu15030614

Figure 2.

Figure 2

Prevalence of patients indicated for IV iron treatment by sex, age, and year (%) for (a) total subjects, (b) men, and (c) women. The x-axis represents age and tested year. The y-axis represents the percentage of patients indicated for reimbursable IV iron treatment. Group 1 was patients with eGFR ≥ 60 mL/min/1.73 m2, Hb ≤ 10 g/dL, and either serum ferritin < 30 ng/mL or TSAT < 20%. Group 2 was patients with eGFR < 60 mL/min/1.73 m2, Hb ≤ 10 g/dL, and either serum ferritin < 100 ng/mL or TSAT < 20%. Group 3 was those with eGFR < 60 mL/min/1.73 m2, Hb ≤ 11 g/dL, and either serum ferritin < 200 ng/mL or TSAT < 20%. Group 4 comprised those with eGFR < 60 mL/min/1.73 m2, Hb ≤ 11 g/dL, and either serum ferritin < 300 ng/mL or TSAT < 30%.